Claims
- 1. An isolated polypeptide comprising an amino acid sequence having at least 80% sequence identity to over the entire length of SEQ ID NO: 2, wherein the percent sequence identity is determined by GAP algorithm under default parameters, wherein the amino acid sequence encodes a polypeptide which specifically binds XRCC3.
- 2. The polypeptide of claim 1 wherein the amino acid sequence has at least 85% sequence identity to SEQ ID NO: 2.
- 3. The polypeptide of claim 1 wherein the amino acid sequence has at least 90% sequence identity to SEQ ID NO: 2.
- 4. The polypeptide of claim 1 wherein the amino acid sequence has at least 95% sequence identity to SEQ ID NO: 2.
- 5. An isolated polypeptide comprising SEQ ID NO: 2.
- 6. An isolated polypeptide comprising an amino acid sequence having at least 80% sequence identity to over the entire length of SEQ ID NO: 2, wherein the percent sequence identity is determined by GAP algorithm under default parameters, wherein the amino acid sequence encodes a polypeptide which forms part of a recombinosome.
- 7. The polypeptide of claim 6 wherein the amino acid sequence has at least 85% sequence identity to SEQ ID NO: 2.
- 8. The polypeptide of claim 6 wherein the amino acid sequence has at least 90% sequence identity to SEQ ID NO: 2.
- 9. The polypeptide of claim 6 wherein the amino acid sequence has at least 95% sequence identity to SEQ ID NO: 2.
- 10. An isolated antibody which is specifically reactive to a Rad51C polypeptide, wherein the antibody is produced using a polypeptide comprising at least 20 contiguous amino acids of SEQ ID NO: 2 as an antigen.
- 11. An isolated polypeptide wherein:
(a) the isolated polypeptide comprises at least 20 contiguous amino acids of SEQ ID NO: 2; (b) the isolated polypeptide, when presented as an immunogen, elicits the production of an antibody which specifically binds to the polypeptide of SEQ ID NO: 2; and (c) the isolated polypeptide does not bind to antisera raised against the polypeptide of SEQ ID NO: 2 after the antisera has been fully immunosorbed with the polypeptide of SEQ ID NO: 2.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. application Ser. No. 09/537,654 filed Mar. 29, 2000, and U.S. application Ser. No. 60/132,582 filed May 5,1999, both of which are herein incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60132582 |
May 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09537654 |
Mar 2000 |
US |
Child |
10818809 |
Apr 2004 |
US |